Regulation of Roche Startup challenge – 2018
Empowering patient data to redefine healthcare
This regulation establishes the rules and conditions to participate in the cultural contest (of a scientific nature, with a focus on innovation) “Empowering patient data to redefine healthcare” (from here on also referred to as “Challenge”), with a national and international scope, promoted by PRODUTOS ROCHE QUÍMICOS E FARMACÊUTICOS S.A, sociedade anônima, with headquarters at Av. Engenheiro Billings, nº 1729, Jaguaré, São Paulo, SP, under nº 33.009.945/0001-23 (“Roche”).
By participating in the Challenge, startups fully accept the terms of this regulation.
The participation in this Challenge is voluntary and free, and is not subordinated to any type of lottery or payment, not bound to the acquisition or use of any good, right or service, under the terms of article 3 of Brazilian Federal Law No. 5,768, dated December 20, 1971, regulated by Decree No. 70.951 of August 9, 1972.
The national and international challenge – “Empowering patient data to redefine healthcare” – has the main and final aim of bringing Roche closer to startup ecosystem, with the goal of forming a network and discussing ideas, projects and possibilities for future partnerships, based on matters/topics related to Roche’s interests.
The ” Empowering patient data to redefine healthcare” challenge proposes that entrepreneurs submit promising projects/solutions developed with the aim of capturing, integrating, handling/processing patient data, developing new predictive models to identify patterns of response to treatments or predisposition of patient populations to certain diseases. This theme is of great relevance to connect patients’ interactions throughout their care journeys (from monitoring to diagnosis, treatment, outcome and post care phase) and for transforming large volumes of healthcare data into knowledge that accelerates research, enhances patient care and improves disease management.
Roche will provide to all participants, regardless of the winner, an online feedback and online evaluation of the submitted projects/solutions, carried out by Roche executives and potentially other partners (to be designated by Roche), contributing to the development of ideas and new business proposals by the startups within the theme of the “Empowering patient data to redefine healthcare” challenge.
3.1. The winning startup may choose 01 (one) of the 03 (three) following awards:
3.1.1 OPTION/AWARD 1: Participation of 02 (two) entrepreneurs of the winning startup in a 03 (three) week immersion program at the Digital Health Accelerator (Werk1, Grafinger Straße 6, München, Germany) from Roche Diagnostics. The immersion program entails networking with digital health startups, with Roche specialists/local investors; a deep-dive week with business coaching, an ExpoDay with executives from Roche/other companies and the possibility to use the co-working space.
22.214.171.124 Roche will cover the following expenses for the 02 (two) entrepreneurs of the winning startup that choose AWARD 1: flight expenses (economy fare) to Munich/Germany, flying out from São Paulo (or from another location, provided the fare is the same); accommodation expenses in Munich, exclusively during the period of the immersion program (Roche will directly book the accommodation). Transfers are not included. In addition, Roche will provide an allowance, in a value to be agreed-upon, to help cover feed costs of the 02 (two) entrepreneurs, exclusively during the period of the immersion program.
126.96.36.199 The 02 (two) entrepreneurs indicated by the winning startup to participate in the immersion program must be proficient in English and also be active partners/employees/collaborators of the startup, with a verifiable employment relationship.
188.8.131.52 The winning startup must participate in the immersion program after the Challenge is closed, within a period agreed-upon with Roche and respecting the availability of the Digital Health Accelerator to receive the startup. The startup and its 02 (two) entrepreneurs must turn up at the location indicated by Roche, within the period agreed-upon with Roche, and provide, at their own expenses, the necessary passports and visas, in case this is required for them to be able to participate in the immersion program. If the winning startup cannot participate in the immersion program or if by any reason the immersion program is cancelled by Roche Diagnostics, the startup must automatically choose one the other award alternatives offered by Roche, no other compensation or indemnification of any nature being due to startup.
3.1.2 OPTION/AWARD 2: Subsidy of corporate services: consulting services, to be provided by a consulting firm appointed by Roche, in the amount of up to 38.000,00 (thirty eight thousand reais), which represents (just as a reference), approximately 10 (ten) days of consulting services, depending on the negotiating conditions to be defined between Roche and a third party (consulting firm). According to the level of maturity of the startup, the consulting firm may provide services to assist in defining the business model, growth strategy or internal structure;
3.1.3 OPTION/AWARD 3: Participation in the Silicon Valley Mission (organized by StartSe), for 01 (one) entrepreneur of the winning startup, including 01 (one) week of visits, lectures and events with entrepreneurs, investors, and professionals from several industries as well as interactive and dynamic workshops with Professors from UC Berkeley and Stanford to motivate a creative and transforming attitude.
184.108.40.206 Roche will cover the following expenses for 01 (one) entrepreneur of the winning startup that choose AWARD 3: flight expenses (economy fare) to Munich/Germany, flying out from São Paulo (or from another location, provided the fare is the same); accommodation expenses in San Francisco, exclusively during the period of the Silicon Valley Mission (Roche will directly book the accommodation). Only internal transfers that cover necessary travels predicted within the Silicon Valley Mission agenda are included. In addition, Roche will provide an allowance, in a value to be agreed-upon, to help cover feed costs of the entrepreneur, exclusively during the period of the Silicon Valley Mission.
220.127.116.11 The winning startup must participate in the immersion program after the Challenge is closed, within a period agreed-upon with Roche and respecting the availability of the Silicon Valley Mission, organized by Startse. The startup and its entrepreneur must turn up at the location indicated by Roche, within the period agreed-upon with Roche, and provide, at his/her own expense, the necessary passports and visas, in case this is required for him/her to be able to participate in the Silicon Valley Mission. If the winning startup cannot participate in the Silicon Valley Mission or if by any reason it is cancelled by Startse, the startup must automatically choose one the other award alternatives offered by Roche, no other compensation or indemnification of any nature being due to the startup.
18.104.22.168 The entrepreneur indicated by the winning startup to participate in the Silicon Valley Mission must be proficient in English and also be an active partner/employee/collaborator of the startup, with a verifiable employment relationship.
3.2 After announcement of the winner (as per section 7 of this regulation), the winning startup has 15 (fifteen) days to inform Roche (by e-mail – the email will be provided during the closing event), of its choice of award.
3.3 If the winning (first-placed) startup cannot benefit from any of the awards offered by Roche, these will be offered to the startup who achieved second place in the Challenge (and so on, in case the second-placed startup cannot benefit from any of the awards), no other prize, compensation or indemnification of any nature being due to the winning startup. The prize must be used by the startup within 6 months after being awarded/after announcing the winning startup at the closing event (as per section 7 of this regulation).
4.1.1. Entries from all Brazilian States and from any other country are considered eligible, provided that: i) the startups are duly constituted in Brazil/their home country and enrolled with a fiscal number (CNPJ for Brazil) by the end of phase II evaluation of the challenge; ii) startups submit projects/solutions that are in one of the stages of development referred to in 4.1.2., and that are related to the challenge theme “Empowering patient data to redefine healthcare”, as described on Annex I.
4.1.2. Startups with projects/solutions in the following stages can participate in the “Empowering patient data to redefine healthcare” challenge:
Beta: the startup has a structured technology/product/service with validation tests, that can include (but are not restricted to) prototype, pilot-tests, minimum viable product (MVP)
Launched: the startup has already completed the testing and validation phase and has introduced the technology/product/service in the market/has users/has concluded the regulatory approval process/needs to gain market share and increase commercial traction.
4.1.3. Startups need to be legally established (with a CNPJ in Brazil/ fiscal number from home country) by the end of phase II of evaluation (even if this is not the case when they initially register through the platform).
4.1.5. The entrepreneurs of the participating startups must be of legal age (as well as the collaborators indicated to participate in the award immersion program, as indicated in item 3 of this regulation), following the Brazilian/their home country legislation.
4.1.6. The solutions submitted by the startups within the context of the “Empowering patient data to redefine healthcare” challenge must have a global context, meaning they should be able to be reproduced in other markets outside Brazil.
5.1 To register to the “Empowering patient data to redefine healthcare” challenge, participants should access the Challenge webpage (www.desafioroche.com.br), create a login and password and fill in the fields of the submission form.
5.2 No other channels are available to send the requested information or any additional material. If any documents are sent through another channel other than the registration form, in no case will they be considered during the selection process. The opening and closing date of entries is communicated on the main page of the challenge.
5.3. The application form consists of questions that seek to collect information about the technology/product/service (or “project” or “solution”) to substantiate the evaluation process. For this reason, most of the information is mandatory. All questions must be answered in Portuguese or English, however we recommend that startups fill the application form in English as Roche will have an international panel evaluating the solutions.
5.3.1 If the startup wishes to submit more than one project/solution to the Challenge, it should do so by registering each project/solution in a separate submission form.
5.3.2 The projects/solutions submitted by the participating startups should be aligned with the Challenge’s theme and address in a clear manner at least one of the items listed under “solutions we are looking for”, as described on Annex I of this regulation. Projects/solutions that do not address any of the listed items will be excluded from the Challenge and will not be evaluated.
5.4. Registration is free.
5.5. Startups are responsible for certifying that they meet the requirements for participation in the “Empowering patient data to redefine healthcare” challenge.
5.6. Except with due and express authorization, if the startup is in any way: i) forbidden (legally or by a third party) of participating in the challenge; ii) breaching any confidentiality obligation; or (iii) infringing third party intellectual property; the startup will be banned from enrolling in the challenge. If Roche becomes aware of such impediments after registration, it may, at any time, disqualify the startup, nothing being due to the startup, and the startup shall remain liable for any related damage caused to Roche.
5.7. If at any stage of the challenge the startup commits an anti-competitive, unethical, unlawful act or an act that is in violation of Roche’s Compliance policy, it will be immediately disqualified from the challenge and may be held liable for such acts.
5.8. The “Empowering patient data to redefine healthcare” challenge will be launched on 02 May 2018 and applications can be submitted until 11:59 PM of 18 June 2018.
6.1. Roche is responsible for evaluating the projects/solutions submitted by startups to the Challenge via the platform (www.desafioroche.com.br).
6.2. The selection process will be carried out by a commission of evaluators made up of Roche’s technical and business specialists and potentially other partners (to be designated by Roche), who guarantee full impartiality to the participating startups.
6.3. The main cycle of the Challenge is structured in 02 (two) steps, the first is the registration step (as indicated in section 5 of this regulation) and the second is the evaluation of the projects/solutions submitted by the participating startups:
Step 1 – ONLINE REGISTRATION – as described on section 5 of this regulation.
Step 2 – EVALUATION – On this stage, the projects/solutions submitted by the startups are evaluated by evaluators from Roche and potentially other partners (to be designated by Roche), in order to identify those with the greatest adherence to the objectives of the challenge, following the criteria described below. This evaluation will be conducted in 02 (two) phases:
Phase I evaluation – Evaluation of the projects/solutions based on the information submitted in the online forms. During this phase, Roche may request startups to send new information or details relative to the projects/solutions already submitted in the platform, which should be provided by the startups up to 05 (five) days after the request from Roche is received. Startups who fail to provide these further information/details may be disqualified.
Phase I evaluation will be based on 06 (six) criteria:
|Strategic fit of the solution with the challenge’s main theme and scalability potential||Evaluates if the proposed solution is already applicable and has results in the challenge’s target market (healthcare) or has the potential of becoming applicable/scalable in that market||1 a 2 – The solution was developed for other markets (other than healthcare) and seems to have considerable barriers to be applicable to the healthcare sector
3 a 4 – The solution was developed for the challenge’s target market (healthcare) but has a low potential of being scalable/applicable to several indications (diseases/treatments)
5 – The solution was developed for the challenge’s target market (healthcare) and has a high potential of being scalable/applicable to several indications (diseases/treatments)
|Innovative character of the solution (technical/business)||Evaluates the degree of innovation in terms of technology and business model or structural/operational change in the market, which translates into the impact and relevance it has/may have for the market/company/society||1 a 2 – the solution presents low innovation grade
3 a 4 – the solution presents medium innovation grade
5 – the solution presents high or disruptive innovation grade
|Maturity||Evaluates the maturity of the solution and its implementation potential||1 – The solution only has a prototype /MVP/pilot tests developed and has not been launched in the market yet
2 a 3 – The solution has already been launched in the market and is operational
4 a 5 – The solution has already been launched in the market, is operational and has all the regulatory aspects covered to allow for the use of the healthcare data
|Differential and tangible benefit||Evaluates how the proposed solution positively differentiates (if the solution is what best suits the need in question) from options already available in the market or under development||1 – The competitive differential is not defined or is not clear
2 a 4 – The competitive differential is partially defined or is not very clear
5 – The competitive differential is defined and is clear
|Consistency and quality of presentation of the project/solution||Evaluates whether the proposed solution is based on information/support plan elaborated with quality, consistency and sufficient detail to fundament its feasibility, innovative character and market differential.||1 – The information/support plan of the proposed solution have no quality/consistency/sufficient details
2 a 4 – Only part of the information/support plan have enough quality/consistency/sufficient details
5 – All the information/support plan have quality/consistency/sufficient details
|Profile of the team||Evaluates whether the entrepreneurs who make up the startup have enough knowledge and experience to develop/execute the solution.||1 – The team does not seem to have enough qualification to execute the project
2 a 4 – The team seems to have enough qualification to execute the project, but would benefit from complementary expertise
5 – The team seems to have great qualification to execute the project
The score of each project/solution from startups in Phase I will be calculated through the weighted average of the 06 (six) criteria (using the respective weights).
Only startups and their respective projects/solutions that meet the following selection criteria during Phase I evaluation will be selected to proceed to Phase II evaluation:
Criteria for selecting startups for Phase II Evaluation:
Minimum score of 3.8 on Phase I
Ranking among the top 10 (ten) projects/solutions in Phase I
Only startups/projects/solutions that meet the 02 (two) abovementioned criteria will be selected. If there is a tie on the list of the best ranked projects/solutions on Phase I, Roche may allow for more than 10 (ten) projects/startups to proceed to Phase II evaluation.
Phase II evaluation – Startups whose projects/solutions are selected on Phase I (see 02 (two) mandatory selection criteria above) will be evaluated in a second phase, Phase II evaluation, based on face‐to‐face or online interviews to be conducted by evaluators from Roche and other potential partners (to be designated by Roche). The evaluation criteria and respective weights of Phase II will be the same as those of Phase I.
At this stage, Roche may, in its sole and exclusive discretion, invite the top 05 (five) classified startups to a “Pitch-Day”, a closing event where startups can present their technologies/products/ services, an opportunity that can foster negotiations and partnerships. By participating in the challenge, startups recognize that the “Pitch‐Day” is neither a promise of investment nor of formulation of partnership with Roche (or with potential Roche guests invited for this event), and nothing can be demanded from startups in this regard.
Failure to show up for Phase II or to the “Pitch-Day” (face-to-face or via online interviews) will be grounds for disqualification of the startup from the Challenge. Participants will be informed of the dates, place and participation requirements through the online platform or by the e-mail registered therein.
The startup with the highest score on Phase II, and with a minimum score of 3,8, will be the winner of the ” Empowering patient data to redefine healthcare” challenge and will be eligible to the prize offered if the startup meets all requirements for receiving the prize, as described on section 3 of this regulation.
If there is a tie in the final score, it will be solved by choosing the team who obtained the highest score in Phase I Evaluation. If the tie still persists, Roche may, in its sole and exclusive discretion, define which startup best fits the goals and theme of the challenge and declare it as winner.
Announcement of the winning startup of the challenge
The announcement of the winning startup of the “Empowering patient data to redefine healthcare” challenge (and respective project/solution) is predicted to occur in October/November 2018, during the closing event of the challenge, and will be published on the same day on the Challenge website (www.desafioroche.com.br).
About the costs
Roche is exempt from any costs referring to the participation of the startups in the challenge. These costs are entirely the responsibility of the startup members. In particular, Roche will not reimburse any expenses related to the transportation/food costs/accommodation for startups to attend on-site/face-to-face events (interviews on Phase II evaluation and/or Pitch-Day).
About media collaboration and image rights
9.1. The participating startups of the “Empowering patient data to redefine healthcare” challenge agree to be available, through their entrepreneurs/indicated representatives, for the relationship with media and communication channels. Participants agree to participate in interviews and reports that may be required, and it is not possible to abstain from these forms of relationships with the communication channels involved in the challenge.
9.2. No participating startup will be required (and it is not advisable that it accepts) to give away any information that he/she believes is confidential or not pertinent to his/her project/solution.
9.3. The participating startups will ensure that all their entrepreneurs/indicated representatives who participate in events related to the Challenge and/or immersion program and/or Silicon Valley Mission, authorize Roche to use their image (and further personality rights, such as voice and name) within the context of the Challenge. The licensed images (and further personality rights) may be linked to and disseminated in the following types of media: printed, televised, video, virtual, social media, and telephone. In addition, Roche may use in its materials the startup name, logotype, name of entrepreneurs, startup description, videos and photos forwarded by the startups, as well as videos and photos containing images from the startup teams, startup presentation, website address, social media (Facebook, twitter and Linkedin), testimonials and any media material produced during the Pitch-Day or on-site/face-to-face events (interviews) at Roche, or provided by the participants.
About the documents
10.1. General guidelines
10.1.1 The documents submitted to the organization of the “Empowering patient data to redefine healthcare” challenge should be of original, innovative and enterprising character or configure market innovation. Plagiarism and/or other infringements to the intellectual property of third parties are expressly forbidden. According to the Brazilian Federal Constitution and the rest of the Brazilian legislation, plagiarism, besides being unconstitutional/illegal, is sufficient grounds to eliminate the startup from the competition, without prejudice to other legal sanctions and implications. By entering the competition, participants attest that the material is original and does not infringe third party intellectual property.
10.2. Failure to meet the deadlines stipulated by the organization of the “Empowering patient data to redefine healthcare” challenge for the delivery of the documents required in each stage is sufficient grounds to eliminate the startup from the competition. In addition, failure to adapt the proposed formatting and restrictions for each type of document requested throughout the challenge is also sufficient grounds to eliminate the startup from the challenge.
About the intellectual property and confidentiality
11.1. The materials submitted by the participants will be stored in the database of the “Empowering patient data to redefine healthcare” challenge, but will remain property of their authors. The contents submitted by the startups will be shared only with Roche and potentially other partners (to be designated by Roche). However, as is usual in this type of competition, despite the fact that those involved are experienced professionals (lawyers, businessmen, executives, investors, among others) who understand the confidential nature of this material, no terms of confidentiality will be required. The participants must assume that any information sent is not protected and should plan accordingly. The participants must adapt their material to present the necessary information without sharing details that jeopardize the startup’s Intellectual Property Protection strategy.
11.2. For startups who do not feel safe in presenting their technology/product/service, the option of signing a confidentiality agreement with Roche may be made available. However, this confidentiality agreement has to be requested at least 03 (three) weeks prior to the application deadline.
12.1. All decisions made by Roche concerning the “Empowering patient data to redefine healthcare” challenge will not be open to appeal.
12.2. All official communication with the participants will be held exclusively via the official online platform of the “Empowering patient data to redefine healthcare” challenge, or by e-mails sent to the addresses registered in the online application form or during the abovementioned steps.
12.3. It is strictly forbidden to use the website to send, exchange or publish any material that is obscene, defamatory or illegal, as well as texts or creations of third parties without the authorization of the author.
12.5. All the submitted projects/solutions must adhere to the general theme of the “Empowering patient data to redefine healthcare” challenge and address at least one of the items described under “solutions we are looking for”, available in ANNEX I of this regulation and on the website.
12.6. At any time, the present challenge may be revoked or annulled, in whole or in part, and its calendar may be modified, without implying the right to indemnity or claim of any nature by any of the participants.
12.7. Failure to comply with the rules described in this document for registration by the applicant startup will entitle Roche to disqualify the startup.
12.8. As indicated in the preamble, the “Empowering patient data to redefine healthcare” challenge is a cultural contest, not related to any type of lottery or payment, not bound to the acquisition or use of any good, right or service, under the terms of article 3 of Brazilian Federal Law No. 5,768, dated December 20, 1971, regulated by Decree No. 70.951 of August 9, 1972.
12.9. By submitting an application to the “Empowering patient data to redefine healthcare” challenge, participating startups (and their respective entrepreneurs/representatives) are agreeing to the terms of this regulation.
12.10 Omitted cases will be deliberated by Roche.
12.11 The challenge and this regulation are governed according to the laws of the Federal Republic of Brazil. Notwithstanding, the Judicial Courts of São Paulo/SP, Brazil, are elected to settle any and all disputes arising out of this regulation and/or the challenge.
ANNEX I – Challenge description and solutions we are looking for
Roche startup challenge 2018
Empowering patient data to redefine healthcare
Healthcare is moving into an era of digital transformation. The last decade has been witnessing a rise in patient data streaming in from several sources – mobile, wearable, electronic records, genomic data, physicians and patients themselves – that are increasingly connected. At Roche, we believe there is a unique opportunity to redefine health care, enabling more personalized patient care by creating and using insights from the access to meaningful data at scale (breadth and depth).
By leveraging the power of multi-sourced data, we can build a more complex, holistic view of patient health and enable better time-to-value decisions throughout the healthcare system.
We are looking for partners sharing our vision and who are tackling this big-data revolution in patient care.
Together we can build a better future.
Start your journey with us today by applying here.
Solutions we are looking for
To apply, your startup should have a solution that addresses at least one of the items described under #GetData or under #Treat and Predict with Data, and that can be reproduced in other markets outside Brazil.
#GetData: We are looking for data acquisition solutions that efficiently capture and connect patients’ interactions throughout their care journeys (from monitoring to diagnosis, treatment, outcome and post care phase).
#Treat and Predict with Data: We are committed to transforming healthcare data into knowledge that allows us to accelerate research, enhance patient care and disease management, and reinforce our partnerships with payers: